Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis

Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women

(2015) Antonino Catalano et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women

(2015) Elena Passeri et al.   International Journal of Endocrinology

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

(2013) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus

(2013) Stefan Kiechl et al.   NATURE MEDICINE

Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study)

(2011) Anne L. Schafer et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women

(2009) Iraj Nabipour et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between Serum Osteocalcin and Markers of Metabolic Phenotype

(2008) Anastassios G. Pittas et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Serum Osteocalcin Level Is Associated with Glucose Metabolism and Atherosclerosis Parameters in Type 2 Diabetes Mellitus

(2008) Ippei Kanazawa et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM